Preclinical imaging in animal models of radiation therapy;Präklinische bildgebung im tiermodell bei strahlentherapie

Radiologe

Volumn 52, Issue 3, 2012, Pages 252-262

  Nikolaou, K ^a   Cyran, C C ^a   Lauber, K ^a   Reiser, M F ^a   Clevert, D A ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Experimental tumor models; Hybrid imaging; Image fusion; Multimodality imaging; Perfusion imaging

Indexed keywords

ANIMAL; ARTICLE; DIAGNOSTIC IMAGING; DISEASE MODEL; HUMAN; IMAGE GUIDED RADIOTHERAPY; METHODOLOGY; NEOPLASM; PROGNOSIS;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS; PROGNOSIS; RADIOTHERAPY, IMAGE-GUIDED;

EID: 84863611081     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-011-2194-y     Document Type: Article

References (72)

1. Neff T, Kiessling F, Brix G et al (2005) An optimized workflow for the integration of biological informa-tion into radiotherapy planning: experiences with T1w DCE-MRI. Phys Med Biol 50:4209-4223 (Pubitemid 41225266)
2. Khoo VS, Joon DL (2006) New developments in MRI for target volume delineation in radiotherapy. Br J Radiol 79(1):2-15
3. MacManus M, Nestle U, Rosenzweig KE et al (2009) Use of PET and PET/CT for radiation therapy plan-ning: IAEA expert report 2006-2007. Radiother Oncol 91:85-94
4. Nestle U, Weber W, Hentschel M, Grosu AL (2009) Biological imaging in radiation therapy: role of po-sitron emission tomography. Phys Med Biol 54:R1-R25
5. Cyran CC, Von Einem J, Paprottka PM et al (2011) Dynamic contrast-enhanced CT imaging biomar-kers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimen-tal prostate carcinomas. Invest Radiol (in press)
6. Cyran CC, Fu Y, Raatschen HJ et al (2008) New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imaging 27:581-589 (Pubitemid 351354744)
7. Turetschek K, Floyd E, Helbich T et al (2001) MRI as-sessment of microvascular characteristics in ex-perimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histo-pathology. J Magn Reson Imaging 14:237-242 (Pubitemid 32801057)
8. Koukourakis MI (2001) Tumour angiogenesis and response to radiotherapy. Anticancer Res 21:4285-4300 (Pubitemid 34240960)
9. Cheng Z, De Jesus OP, Namavari M et al (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 49:804-813 (Pubitemid 351717547)
10. Patel D, Kell A, Simard B et al (2011) The cell labe-ling efficacy, cytotoxicity and relaxivity of copper-activated MRI/PET imaging contrast agents. Bio-materials 32:1167-1176
11. Cyran CC, Paprottka PM, Von Einem J et al (2010) Perfusion MRI for monitoring sorafenib effect on experimental prostate carcinomas: a validation study. AJR Am J Roentgenol (in press)
12. Bumb A, Regino CA, Perkins MR et al (2010) Prepa-ration and characterization of a magnetic and op-tical dual-modality molecular probe. Nanotechno-logy 21:175704
13. Makowski MR, Wiethoff AJ, Blume U et al (2011) Assessment of atherosclerotic plaque burden with an elastin-specific magnetic resonance contrast agent. Nat Med 17:383-388
14. Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508:333-348
15. Frahm J, Michaelis T, Merboldt KD et al (1989) Lo-calized NMR spectroscopy in vivo. Progress and problems. NMR Biomed 2:188-195
16. Majos C, Alonso J, Aguilera C et al (2002) Adult pri-mitive neuroectodermal tumor: proton MR spec-troscopic findings with possible application for dif-ferential diagnosis. Radiology 225:556-566 (Pubitemid 35239262)
17. Stadlbauer A, Gruber S, Nimsky C et al (2006) Preo-perative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 238:958-969 (Pubitemid 43289928)
18. Kuroda K, Suzuki Y, Ishihara Y, Okamoto K (1996) Temperature mapping using water proton chemi-cal shift obtained with 3D-MRSI: feasibility in vivo. Magn Reson Med 35:20-29
19. Sourbron S (2010) Technical aspects of MR perfusi-on. Eur J Radiol 76:304-313
20. Cyran CC, Paprottka PM, Schwarz B et al (2011) Perfusion MRI for monitoring sorafenib effect on experimental prostate carcinomas: a validation study. AJR Am J Roentgenol (in press)
21. Fung SH, Roccatagliata L, Gonzalez RG, Schaefer PW (2011) MR diffusion imaging in ischemic stro-ke. Neuroimaging Clin North Am 21:345-377
22. Choi SH, Paeng JC, Sohn CH et al (2011) Correlati-on of 18F-FDG uptake with apparent diffusion co-efficient ratio measured on standard and high b value diffusion mri in head and neck cancer. J Nucl Med 52(7):1056-1062
23. Inglese M, Bester M (2010) Diffusion imaging in multiple sclerosis: research and clinical implicati-ons. NMR Biomed 23:865-872
24. Bowers CR, Weitekamp DP (1986) Transformation of symmetrization order to nuclear-spin magnet-ization by chemical reaction and nuclear magnetic resonance. Phys Rev Lett 57:2645-2648
25. Olsson LE, Chai CM, Axelsson O et al (2006) MR co-ronary angiography in pigs with intraarterial injec-tions of a hyperpolarized 13C substance. Magn Re-son Med 55:731-737
26. Svensson J, Mansson S, Johansson E et al (2003) Hyperpolarized 13C MR angiography using true-FISP. Magn Reson Med 50:256-262 (Pubitemid 36950844)
27. Golman K, Zandt RI, Lerche M et al (2006) Metabo-lic imaging by hyperpolarized 13C magnetic reso-nance imaging for in vivo tumor diagnosis. Cancer Res 66:10855-10860 (Pubitemid 44876982)
28. Mansson S, Johansson E, Magnusson P et al (2006) 13C imaging-a new diagnostic platform. Eur Radi-ol 16:57-67 (Pubitemid 43103569)
29. Cyran CC, Von Einem JC, Paprottka PM et al (2011) Dynamic contrast-enhanced computed tomogra-phy imaging biomarkers correlated with immuno-histochemistry for monitoring the effects of sora-fenib on experimental prostate carcinomas. Invest Radiol, in press
30. Ophir J, Cespedes I, Ponnekanti H et al (1991) Elastography: a quantitative method for imaging the elasticity of biological tissues. Ultrason Ima-ging 13:111-134
31. De Zordo T, Chhem R, Smekal V et al (2010) Real-time sonoelastography: findings in patients with symptomatic achilles tendons and comparison to healthy volunteers. Ultraschall Med 31:394-400
32. Krouskop TA, Wheeler TM, Kallel F et al (1998) Elas-tic moduli of breast and prostate tissues under compression. Ultrason Imaging 20:260-274 (Pubitemid 29168827)
33. Itoh A, Ueno E, Tohno E et al (2006) Breast disease: clinical application of US elastography for diagno-sis. Radiology 239:341-350
34. Lorenz A, Ermert H, Sommerfeld HJ et al (2000) Ultrasound elastography of the prostate. A new technique for tumor detection. Ultraschall Med 21:8-15 (Pubitemid 30148888)
35. Van Vledder MG, Boctor EM, Assumpcao LR et al (2010) Intra-operative ultrasound elasticity ima-ging for monitoring of hepatic tumour thermal ab-lation. HPB (Oxford) 12:717-723
36. Zhang D, Zhang S, Wan M, Wang S (2011) A fast tis-sue stiffness-dependent elastography for HIFU-in-duced lesions inspection. Ultrasonics 51:857-869
37. Chenot J, Melodelima D, N'Djin WA et al (2010) Int-ra-operative ultrasound hand-held strain imaging for the visualization of ablations produced in the liver with a toroidal HIFU transducer: first in vivo results. Phys Med Biol 55:3131-3144
38. Cui LG, Shao JH, Wang JR et al (2009) Ultrasound elastography of ethanol-induced hepatic lesions: in vitro study. Chin Med Sci J 24:81-85
39. Hoyt K, Forsberg F, Merritt CR et al (2005) In vivo elastographic investigation of ethanol-induced he-patic lesions. Ultrasound Med Biol 31:607-612 (Pubitemid 40615180)
40. Clevert D-A, Sommer WH, Helck A, Reiser M (2011) Duplex and contrast enhanced ultrasound (CEUS) in evaluation of in-stent restenosis after carotid stenting. Clin Hemorheol Microcirc 48:199-208
41. Clevert D-A, Minaifar N, Kopp R et al (2009) Ima-ging of endoleaks after endovascular aneurysm repair (EVAR) with contrast-enhanced ultrasound (CEUS). A pictorial comparison with CTA. Clin He-morheol Microcirc 41:151-168
42. Helck A, Sommer WH, Wessely M et al (2011) Bene-fit of contrast enhanced ultrasound for detection of ischaemic lesions and arterio venous fistulas in renal transplants - a feasibility study. Clin Hemor-heol Microcirc 48:149-160
43. Clevert D-A, Sommer WH, Helck A et al (2011) Im-proved carotid atherosclerotic plaques imaging with contrast-enhanced ultrasound (CEUS). Clin Hemorheol Microcirc 48:141-148
44. Clevert D-A, Helck A, Paprottka PM et al (2011) La-test developments in ultrasound of the liver. Ra-diologe 51:661-670
45. Zengel P, Schrotzlmair F, Kramer M et al (2011) Ma-nagement of salivary gland diseases with contrast-enhanced ultrasound. Radiologe 51:490-496
46. Clevert D-A, Helck A, Paprottka PM et al (2011) Contrast-enhanced ultrasound imaging of the ca-rotid artery. Radiologe 51:483-489
47. Jung EM, Uller W, Stroszczynski C, Clevert D-A (2011) Contrast-enhanced sonography. Therapy control of radiofrequency ablation and transarte-rial chemoembolization of hepatocellular carcino-ma. Radiologe 51:462-468
48. Schwarz F, Sommer WH, Reiser M, Clevert D-A (2011) Contrast-enhanced sonography for blunt force abdominal trauma. Radiologe 51:475-482
49. Greis C (2011) Summary of technical principles of contrast sonography and future perspectives. Ra-diologe 51:456-461
50. Greis C (2009) Ultrasound contrast agents as mar-kers of vascularity and microcirculation. Clin He-morheol Microcirc 43:1-9
51. Paprottka PM, Zengel P, Ingrisch M et al (2011) Contrast-enhanced ultrasound in animal models. Radiologe 51:506-513
52. Van Persijn van Meerten EL, Gelderblom H, Bloem JL (2010) RECIST revised: implications for the ra-diologist. A review article on the modified RECIST guideline. Eur Radiol 20:1456-1467
53. Topp KA, Zachary JF, O'Brien WD Jr (2001) Quanti-fying B-mode images of in vivo rat mammary tu-mors by the frequency dependence of backscatter. J Ultrasound Med 20:605-612 (Pubitemid 32499943)
54. Paprottka PM, Cyran CC, Zengel P et al (2010) Non-invasive contrast enhanced ultrasound for quanti-tative assessment of tumor microcirculation. Con-trast mixed mode examination vs. only contrast enhanced ultrasound examination. Clin Hemor-heol Microcirc 46:149-158
55. Stieger SM, Bloch SH, Foreman O et al (2006) Ult-rasound assessment of angiogenesis in a matrigel model in rats. Ultrasound Med Biol 32:673-681
56. Lassau N, Chami L, Chebil M et al (2011) Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med 11:18-24
57. Luker GD, Luker KE (2008) Optical imaging: cur-rent applications and future directions. J Nucl Med 49:1-4
58. Backer MV, Gaynutdinov TI, Patel V et al (2005) Va-scular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 4:1423-1429
59. Deliolanis N, Lasser T, Hyde D et al (2007) Free-space fluorescence molecular tomography utili-zing 360 degrees geometry projections. Opt Lett 32:382-384 (Pubitemid 46354030)
60. Ntziachristos V, Tung CH, Bremer C, Weissleder R (2002) Fluorescence molecular tomography resol-ves protease activity in vivo. Nat Med 8:757-760 (Pubitemid 34778731)
61. Zavattini G, Vecchi S, Mitchell G et al (2006) A hy-perspectral fluorescence system for 3D in vivo op-tical imaging. Phys Med Biol 51:2029-2043
62. Ntziachristos V (2011) Clinical translation of optical and optoacoustic imaging. Philos Transact A Math Phys Eng Sci 369:4666-4678
63. Ntziachristos V, Chance B (2001) Probing physiolo-gy and molecular function using optical imaging: applications to breast cancer. Breast Cancer Res 3:41-46 (Pubitemid 32223652)
64. Pichler BJ, Wehrl HF, Judenhofer MS (2008) Latest advances in molecular imaging instrumentation. J Nucl Med 49(Suppl 2):5-23
65. Kim MJ (2011) Current limitations and potential breakthroughs for the early diagnosis of hepato-cellular carcinoma. Gut Liver 5:15-21
66. Cyran CC, Sennino B, Chaopathomkul B et al (2008) Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature. Invest Radi-ol 43:298-305 (Pubitemid 351572206)
67. Cyran CC, Sennino B, Chaopathomkul B et al (2009) Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. Eur Radiol 19:121-131
68. Cyran CC, Sennino B, Fu Y et al (2011) Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF). Eur J Radiol [Epub ahead of print]
69. Sipkins DA et al (1998) Detection of tumor angio-genesis in vivo by alphavbeta3-targeted magnetic resonance imaging. Nat Med 4(5):623-626 (Pubitemid 28237365)
70. Winter PM et al (2003) Molecular imaging of an-giogenesis in nascent Vx-2 rabbit tumors using a novel alpha (nu) beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 63(18):5838-5843 (Pubitemid 37187482)
71. Brockenbrough JS et al (2012) Kinetic analysis of 18-F-FLT PET in lung tumors. J Nucl Med [Epub ahead of printj
72. Lopci E et al (2010) Imaging with non-FDG PET tracers: outlook for current clinical applications. Insights Imaging 1:373-385